J&J Covid19 vaccine trials in India unlikely, is it true?

    Johnson & Johnson is unlikely to undertake local bridging trials for its single-shot COVID-19 vaccine in India, the Economic Times reported on Tuesday, citing a company spokesperson.

    While J&J had sought approval for conducting bridging trials in the country, the U.S.-based drugmaker said it wouldn’t have to do that now since India has scrapped that requirement, according to the report.

    The company is exploring how to accelerate the availability of its vaccine in India, the Economic Times said.

    J&J said in April it was in talks with India’s government to begin a bridging clinical study of its Janssen COVID-19 vaccine candidate in the country.

    In late May, India said it would scrap local trials altogether for “well-established” vaccines manufactured in other countries.

    Over 41 million COVID-19 vaccine doses were administered across India last week, with pandemic-induced restrictions being eased further.

    Experts have said widespread vaccination remains one of the best tools to avoid the kind of devastation India saw during its second wave of the pandemic.

    There is no official confirmation yet from J&J while the reports suggest quoted from unnamed officials from the company. will await official confirmation and report further.


    Latest Updates

    Related Articles

    Greenko builds renewable garages for Formula E cars in Hyderabad

    Hyderabad, 3rd February 2023: The countdown to the highly anticipated FIA Formula E 2023...

    2023: Check Out Sachin Tendulkar’s New Food Obsession

    The God of Cricket, Sachin Tendulkar, has taken a break from hitting home runs...

    Budget 2023: Saptarshis Guiding India Through Amrit Kaal, Big Tax Relief for the Middle Class

    New Delhi, India, Budget 2023 - The Finance Minister of India, Smt. Nirmala Sitharaman...

    2023 Greenko Hyderabad E-Prix: ‘Track is on Track’ – Arvind Kumar IAS

    The preparations for the Formula E 2023 Greenko Hyderabad E-Prix in Hyderabad is at...